Patients requiring kidney transplantation, for example, can be administered E2 in advance to activate ERα or administered TGF-BR1 antagonists to inhibit the SMAD pathway and thereby reduce inflammatory mediator production and renal fibrosis. The gene discussed is TGFBR1; the disease is renal fibrosis.